High‐dose chemotherapy with autologous stem cell transplantation spares re‐irradiation for recurrent intracranial germinoma
Pediatric Blood & Cancer2018Vol. 65(8), pp. e27104–e27104
Citations Over Time
Hirohito Kubota, Katsutsugu Umeda, Kagehiro Kouzuki, Kuniaki Tanaka, Tomoo Daifu, Takayuki Hamabata, Seishiro Nodomi, Itaru Kato, Hidefumi Hiramatsu, Yoshiki Arakawa, Takashi Mizowaki, Souichi Adachi
Abstract
The clinical outcome of high-dose chemotherapy (HDC) with autologous stem cell transplantation was retrospectively analyzed in six patients with recurrent intracranial germinoma. Prior to HDC, all patients achieved complete remission after platinum and ifosfamide-based chemotherapy. A melphalan-based conditioning regimen was administered in either a single cycle or multiple sequential cycles. Five of the six patients are alive and free from disease, with a median survival of 65 months, among which four patients avoided re-irradiation. In a significant proportion of patients, recurrent intracranial germinoma is curable by HDC without re-irradiation, provided that the disease remains sensitive to salvage chemotherapy.
Related Papers
- → Efficacy of Ifosfamide-Cisplatin-Etoposide (ICE) Chemotherapy for a CNS Germinoma in a Child With Down Syndrome(2016)11 cited
- → Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning – evidence for a superior outcome using melphalan combined with total body irradiation(2005)41 cited
- Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.(1988)
- → Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning(2018)7 cited
- → The antileukaemic action of melphalan and total body irradiation in bone marrow transplantation(1991)